University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Faculty Scholarship
7-2009

Metabolic Syndrome and Risk of Cancer Mortality in Men
Jason R. Jaggers
University of Louisville, jason.jaggers@louisville.edu

Xuemei Sui
University of South Carolina

Steven P. Hooker
University of South Carolina

Michael J. LaMonte
University of Buffalo

Charles E. Matthews
Vanderbilt University
See next page for additional authors
Follow this and additional works at: https://ir.library.louisville.edu/faculty
Part of the Endocrinology, Diabetes, and Metabolism Commons, and the Sports Sciences Commons

Original Publication Information
Jaggers, Jason R., Xuemei Sui, Steven P. Hooker, Michael J. LaMonte, Charles E. Matthews, Gregory A.
Hand, Steven N. Blair. "Metabolic syndrome and risk of cancer mortality in men." 2009. European Journal
of Cancer 45(10): 1831-1838.
https://doi.org/10.1016/j.ejca.2009.01.031

ThinkIR Citation
Jaggers, Jason R.; Sui, Xuemei; Hooker, Steven P.; LaMonte, Michael J.; Matthews, Charles E.; Hand,
Gregory A.; and Blair, Steven N., "Metabolic Syndrome and Risk of Cancer Mortality in Men" (2009). Faculty
Scholarship. 464.
https://ir.library.louisville.edu/faculty/464

This Article is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional
Repository. It has been accepted for inclusion in Faculty Scholarship by an authorized administrator of ThinkIR: The
University of Louisville's Institutional Repository. For more information, please contact thinkir@louisville.edu.

Authors
Jason R. Jaggers, Xuemei Sui, Steven P. Hooker, Michael J. LaMonte, Charles E. Matthews, Gregory A.
Hand, and Steven N. Blair

This article is available at ThinkIR: The University of Louisville's Institutional Repository: https://ir.library.louisville.edu/
faculty/464

NIH Public Access
Author Manuscript
Eur J Cancer. Author manuscript; available in PMC 2010 July 1.

NIH-PA Author Manuscript

Published in final edited form as:
Eur J Cancer. 2009 July ; 45(10): 1831–1838. doi:10.1016/j.ejca.2009.01.031.

Metabolic Syndrome and Risk of Cancer Mortality in Men
Jason R. Jaggersa,*, Xuemei Suia, Steven P. Hookera, Michael J. LaMonteb, Charles E.
Matthewsc, Gregory A. Handa, and Steven N. Blaira,d
a Department of Exercise Science, Arnold School of Public Health, University of South Carolina, Columbia,
SC
b Department of Social and Preventive Medicine, University of Buffalo, Buffalo, NY
c Vanderbilt University Medical Center, Institute for Medicine and Public Health, Vanderbilt-Ingram Cancer
Center, Nashville, TN
d Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South
Carolina, Columbia, SC

NIH-PA Author Manuscript

Abstract
Background—Metabolic syndrome (MetS) has been linked with an increased risk of developing
cancer; however the association between MetS and cancer mortality remains less clear. Little research
has focused on pre-cancer risk factors that may affect the outcome of treatment. The purpose of this
study was to examine the association between MetS and all-cancer mortality in men.
Methods—The participants included 33,230 men aged 20-88 years who were enrolled in the
Aerobics Center Longitudinal Study and free of known cancer at baseline.
Results—At baseline 28% of all the participants had MetS. During an average of 14 years followup there were a total of 685 deaths due to cancer. MetS at baseline was associated with a 56% greater
age-adjusted risk in cancer mortality.
Conclusion—These data show that MetS is associated with an increased risk of all-cause cancer
mortality in men. Based on these findings it is evident that successful interventions should be
identified to attenuate the negative effects of MetS.
Keywords
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1. Introduction
Metabolic syndrome (MetS) is defined as having any 3 of the following 5 components:
abdominal obesity, high blood pressure, high fasting triglycerides, low fasting high density
lipoprotein-cholesterol (HDL-C), and high fasting glucose (1,2). Recent evidence indicates
that one in five adults in the U.S. have coexisting risk factor abnormalities that meet the criteria
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for MetS (1,3). Several studies have shown that the presence of MetS increases risk for type
II diabetes, cardiovascular disease (CVD), as well as all-cause and CVD mortality(4-6).
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There is growing interest in a potential etiological role for MetS and the development of cancer
(1,4,7-12). Studies have shown that each of the MetS components may independently increase
the risk for developing certain types of cancer (2,3,10,12,13). For example, investigations have
demonstrated abdominal obesity to be a positive risk factor for an increased risk of
endometrium, breast, colon, liver, gallbladder, esophagus, and kidney cancers (7). In addition,
impaired glucose regulation and dyslipidemia (suppressed HDL-C and/or elevated
triglycerides) have also been shown to increase one's risk of colon, breast, and/or prostate
cancers (1,9,10,13).
Findings from a small number of studies have suggested a positive association between MetS
and risk of colorectal cancer mortality (12,14). Other studies have shown a greater risk of
colorectal cancer mortality associated with the presence of MetS compared to that associated
with the individual MetS components alone (1). Additional prospective data are needed to
further examine the role of MetS in cancer prognosis. The purpose of this study was to examine
the association between MetS and all-cause cancer mortality in a large cohort of men enrolled
in the Aerobics Center Longitudinal Study (ACLS).
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2. Materials and Methods
2.1 Study Population
Participants were 33,230 men aged 20-88 years who, at baseline, were free of known cancer,
completed a preventive medical examination at the Cooper Clinic (Dallas, TX) between 1977
and 2003, and are enrolled in the ACLS. Study participants came to the clinic for periodic
preventive health examinations and for counseling regarding diet, exercise, and other lifestyle
factors associated with increased risk of chronic disease. Many participants were referred by
their employers for the examination, others were referred by their personal physicians, and
some were self-referred. All participants in the current analysis had complete measures for
each metabolic syndrome component. Most of the participants were white, well-educated, and
from middle to upper socioeconomic strata. All participants provided written informed consent
to participate in the follow-up study and the Cooper Institute institutional review board
approved the study protocols annually.
2.2 Clinical Data
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Participants completed a comprehensive health evaluation that included self-reported personal
and family health histories; a standardized medical examination by a physician; anthropometric
measures; a maximal treadmill exercise test; and a fasting venous blood draw. Examination
procedures followed a standard manual of operations and have been previously described in
greater detail (15,16). Briefly, body mass index (BMI, kg/m2) was computed from measured
height and weight. Waist circumference was measured at the level of the umbilicus. Resting
blood pressure was recorded as the first and fifth Korotkof sounds by auscultatory methods
(17). Serum samples were analyzed for total cholesterol, HDL-C, triglyceride, and glucose
using standardized automated bioassays that met Centers for Disease Control and Prevention
standards of the Lipid Standardization Program. Information on smoking habits (never, current,
or past smoker), alcohol intake (drinks per week), personal history of hypertension, diabetes,
hypercholesterolemia, and cardiovascular disease (myocardial infarction or stroke), and family
history of cancer was obtained from a standardized questionnaire. Physical inactivity was
assessed using a questionnaire and was defined as reporting no leisure-time physical activity
in the 3 months before the baseline examination. Cardiorespiratory fitness was quantified as
the duration of a symptom-limited maximal treadmill exercise test using a modified Balke
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protocol (16,18). The duration of the test on this protocol is highly correlated (r = 0.92) with
directly measured maximal oxygen uptake in men (19). To standardize exercise test
performance, we computed maximal metabolic equivalents (METs, 1 MET = 3.5 ml O2 uptake/
kg/min) of cardiorespiratory fitness based on the final treadmill speed and grade (20).
2.3 Metabolic Syndrome Definition
Participants were classified as having metabolic syndrome using criteria of the National
Cholesterol Education Program Adult Treatment Panel III, and were based on the presence of
3 or more of the following risk factors (21) : 1) abdominal obesity (waist girth > 102 cm); 2)
fasting hypertriglyceridemia (≥ 150 mg/dL); 3) low HDL cholesterol (<40 mg/dL); 4) high
blood pressure (≥130/85 mmHg); and 5) high fasting glucose (≥110 mg/dL). History of
physician-diagnosed hypertension and diabetes also were used to identify men who met criteria
for high blood pressure and glucose, respectively, as done in other epidemiological studies
(22,23) and in our previous report (24).
2.4 Mortality Surveillance
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Participants were followed from the date of their baseline examination until the date of death
or until the time of censoring, December 31, 2003. Person-years of exposure were computed
as the sum of follow-up time among decedents and survivors. The National Death Index (NDI)
was the primary data source for mortality surveillance. The underlying cause of death was
determined from the NDI report or by a nosologist's review of official death certificates
obtained from the department of vital records in the decedent's state of residence at time of
death. Causes of cancer death were identified using International Classification of Diseases,
Ninth Revision (ICD-9) codes for deaths occurring before 1999 and Tenth Revision (ICD-10)
codes (in parentheses) for deaths during 1999-2003: Our primary outcome for this analysis
was total cancer mortality, 140-208 (C00-C97); and secondary outcomes were: Lung,
1622-1625, 1628-1629 (C340-C343, C348-C349); Colon, 153 (C18); Rectum,154 (C19-C21);
and Prostate, 185 (C60) cancer mortality. These secondary outcomes were chosen to confirm
results of other investigators. Additionally they were the only cancers reported in our
population to make a strong comparison.
2.5 Statistical Analysis
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Characteristics of the cohort at baseline were compared by exposure status using t- tests and
χ2 tests. Kaplan-Meier survival curves were generated for MetS and according to the number
of prevalent MetS risk factors. Cox proportional hazards regression analysis was used to
estimate multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CI). Tests
for linear trend of HRs across exposure groups were obtained using ordinal scoring. Two types
of Cox regression models were fit to the follow-up data. First, we estimated the associations
adjusting only for baseline age (years). Second, we adjusted for baseline age (years),
examination year (calendar year), height (cm), smoking status (never, past, or current smoker),
alcohol intake (≥5 drinks/wk or not), physically inactive (yes/no), hypercholesterolemia (yes/
no), cardiovascular disease (yes/no), family history of cancer (yes/no), and cardiorespiratory
fitness (treadmill test duration in minutes). These are common covariates adjusted for in cancer
risk investigations. However, cardiorespiratory fitness and/or physical inactivity were not
generally included in the adjusted models, and appear to be a novel inclusion in the current
investigation. Cumulative hazard plots grouped by exposure suggested no appreciable
violations of the proportional hazards assumption. Because of the known correlation between
BMI and several of the MetS components, we elected not to include it as a covariate in our
models, but we do consider the combined effect of BMI and other exposures on mortality risk
in joint analyses described below.
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We estimated cancer mortality risk based on joint exposure to MetS (present or not) and age
(20-39, 40-59, ≥ 60 yrs), BMI (< 25, ≥ 25 kg/m2), and smoking status (never, past, and current
smoker). Multiplicative interaction was tested by fitting each of these terms and their crossproduct along with the covariates in the multivariate-adjusted model. We also completed our
primary analyses after excluding deaths that occurred in the first five years of follow-up.
Similar patterns of association were observed in these analyses. Statistical analyses were
performed using SAS (version 9.1, SAS Institute, Cary, NC) software. All p values were
obtained from two-sided hypothesis tests.

3. Results
At baseline, the prevalence of MetS was 27.9%. A comparison of baseline characteristics of
those with and without MetS are presented in Table 1. Those without MetS were younger, had
a more favorable lipids and glucose profile, were less likely to be physically inactive or a current
smoker, consumed 5 or more alcoholic beverages per week, had higher maximal
cardiorespiratory fitness, a lower prevalence of any of the five MetS components, as well as
fewer cases of chronic medical conditions compared to those with MetS.
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There were 685 deaths due to cancer during an average of 14 ± 7 years follow-up. Table 2
presents the hazard ratios and confidence intervals for all-cause cancer mortality associated
with MetS. Baseline MetS was associated with a 56% greater age-adjusted risk of cancer
mortality compared with absence of this condition (P < 0.0001). After multivariate adjustment,
this association remained significant (P < 0.001). In addition, there was a graded increase in
risk associated with a greater number of prevalent MetS components (P for trend < 0.001).
Compared to men with 0 components, those with 3 or more components had an 83% higher
risk of cancer death.
We also evaluated cancer mortality risk associated with individual MetS components (Table
2). We found a positive multivariable-adjusted association between cancer mortality and four
of the five MetS components: abdominal obesity increased risk by 28% (P = 0.01); high
triglycerides increased risk by 25% (P = 0.009); low HDL-C increased risk by 25% (P = 0.007);
and high glucose increased risk by 22% (P = 0.01). High blood pressure was the only component
that did not increase risk (P = 0.18) in the fully adjusted model.
Kaplan-Meier plots for the presence of MetS and according to the number of prevalent MetS
components are shown in Figure 1. Prognosis was worse among those with MetS (Panel 1A)
and with increasing number of prevalent MetS components (Panel 1B; P < 0.0001 for each).
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When evaluating cause-specific cancer mortality (Table 3), the presence of MetS was
significantly associated with increased risk for lung (P < 0.0001) and colorectal cancer (P =
0.004), but not prostate cancer (P = 0.31). However, the positive associations were attenuated
in the fully adjusted models.
Finally, we examined the risk of cancer mortality based on the joint effects of MetS and other
risk factors (Table 4). For this analysis, the referent group was comprised of men who did not
have MetS and were at lowest risk stratum for the other factor. Among men without MetS,
older men (age 40-59 years) and current smokers were at higher risk than younger men (age
<40 years) and those who were past smokers. There was no elevation in risk in men without
MetS who had a BMI ≥25.0. Men with MetS had higher risk for cancer death than men in the
reference category for all comparisons except for past smokers.
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4. Discussion
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In this large prospective study, a positive association was found between MetS and all-cause
cancer mortality in men. We also found that MetS was associated with a higher mortality risk
for lung and colorectal cancers. These associations were robust even after adjusting for a
number of potential confounders; however, only lung cancer remained statistically significant.
Cancer mortality risk was significantly higher with an increasing number of MetS components
present at baseline. Assessment of the joint associations between MetS and other risk factors
indicated that cancer mortality risk associated with MetS was particularly higher for men who
were over 40 years of age, overweight or obese, or current smokers.
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Previous epidemiological investigations have found that individual components of MetS are
associated with higher risk of developing cancer; however, the data examining risk of cancer
mortality following exposure to MetS are more sparse. Only three epidemiological
investigations have looked at the risk of cancer mortality associated with MetS. These studies
focused on site-specific mortality such as colorectal (12,14) and prostate (25) cancer, and
different criteria have been used to define MetS across studies. Trevisan et al. (12) pooled data
from The Risk Factors and Life Expectancy Project, which represents nine different large-scale
epidemiological studies with a total of 21,311 men and 15,991 women included in data analysis.
They found that both men and women who exhibited MetS had a nearly 3-fold increase in risk
of dying from colon cancer compared to those without MetS. In another report, Colangelo et
al. (14) studied 20,433 men and 15,149 women and showed that the risk of colorectal cancer
mortality was 67% greater in men and 29% greater in women who had 3-4 MetS components
as compared with their peers who had no prevalent MetS components. Our findings are
consistent with these studies regarding an increased risk of colorectal cancer mortality in men
with MetS.
Recently, Hsing et al. (8,25) reviewed published studies on MetS components and prostate
cancer. They found only one investigation in which fatal cases of prostate cancer had a higher
BMI, waist to hip ratio, and systolic blood pressure. However, since each of these components
was analyzed individually the investigators were unable to determine if the presence of MetS,
per se, or simply a greater number of prevalent MetS components was associated with the risk
of prostate cancer mortality. Thus, it was concluded that the epidemiological evidence is
insufficient to suggest a link between MetS and prostate cancer mortality. Our findings are
consistent with the conclusions of Hsing et al. (25).
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MetS is a complex multi-factorial condition, and, therefore, several plausible mechanisms may
be involved with the higher risk of all-cause cancer mortality. Numerous investigations have
shown that many of the individual MetS components increase the risk of developing cancer
(i.e., obesity, insulin resistance, hypertension and high triglycerides), some more specific to
certain types of cancers than others (9,13,26-28). For example, it is well known that obesity is
an important risk factor for cancer mortality, and one large prospective study indicated that
obesity accounted for 14% of all cancer deaths in men and 20% in women (26).
Although the mechanisms behind the associated increase in cancer risk and/or mortality are
not completely understood, previous data suggests insulin resistance to be one of the underlying
mechanisms of MetS, and possibly cancer cell proliferation. Additionally, many metabolic
abnormalities related to insulin resistance are closely associated with obesity and weight
change (29). In a literature review by Giovannuci (29), strong evidence in animal models was
compiled directly implicating a cancer-enhancing effect of insulin. Findings from the
investigations included in the review demonstrated growth of aberrant crypt foci, a colorectal
cancer precursor, as well as increasing the number and size of tumors, was enhanced by insulin
injections. These findings were later replicated in a more natural setting in which rats were fed
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a high energy, high fat diet which led to insulin resistance and impaired glucose tolerance
(29,30).
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Additionally, it is well known that insulin is a major anabolic hormone that can stimulate cell
proliferation. It has been proposed that an indirect mechanism may be involved in the effects
of insulin on cancer cell proliferation in vivo, such as insulin-like growth factor (IGF)-1
stimulation which plays an important role to cellular proliferation in response to nutrient
availability (1). IGF-1 production has been shown to be stimulated by insulin via up-regulation
of growth hormones in the liver (29). Furthermore, IGF-1 bioavailability can be increased
during hyperinsulinemic conditions by decreasing hepatic secretion of IGF binding protein 1
and 2 so that more IGF-1 is free to bind to its receptor on normal cancerous cells. Over
expression of IGF-1 receptors have been observed in breast and colon cancers (31). Human
evidence has also demonstrated positive associations among high levels of insulin and IGF-1
and risk of colon cancer (28).
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The proposed biologic mechanisms discussed are specific to the development of colon cancer.
Although the current investigation focused on risk of cancer mortality, and not specifically
incident cancer risk, we found a significantly higher risk of mortality from colon and rectal
cancer combined in those with MetS or in the presence of multiple MetS components. This
would suggest that similar mechanisms may be responsible for the increased risk of mortality
from colorectal cancer in human models.
Based on the findings of this current investigation, it is evident that individuals who exhibited
multiple components of MetS had higher risk of cancer mortality. One strength of the current
study is that we compared the risk of all-cause cancer mortality associated with MetS, whereas
previous investigations focused solely on risk of incident colon, rectum, or prostate cancer.
However, an interesting finding that, to our knowledge has not yet been reported, is the
significant association of MetS with a higher risk of lung cancer mortality in men. More work
needs to be done to replicate or refute this novel finding.
Additional strengths of the current study include the extensive baseline examination to detect
subclinical disease, use of measured risk factors, and large number of person-years of followup. The associations generally were independent of traditional risk factors, a result that
strengthens causal inferences. As discussed earlier, these associations may be biologically
plausible, although the precise mechanisms remain unknown.
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There also are limitations to this investigation. Due to the analyses of only a male population,
we can not conclude whether or not similar results would be observed in women. Past studies
have shown that women have a lower risk of cancer mortality following exposure to MetS
(1,12,14). In addition, the homogeneity of our population sample may limit the generalizability
of our findings to men of other races/ethnicities, income levels, or educational attainment, but
it should not affect the internal validity of our results. We also did not have sufficient data
collection on medications or dietary habits to include in our analysis. It is important to note
that when it comes to risk of cancer mortality, consideration must be taken into account for
daily changes in lifestyle habits, progressive advancements in medical treatment/prevention,
and successful elimination of any MetS component present at baseline. However, we have no
such data available. Future studies with such information will need to confirm our findings
reported here.
In conclusion, the presence of MetS or a greater number of MetS components were associated
with a significantly higher risk for all-cause cancer mortality, as well as lung and colorectal
cancer mortality. According to our findings, a dose-response relationship appears to exist
between the number of MetS components and the higher risk of all-cause cancer mortality,
with the risk associated with the presence of three or more components being particularly
Eur J Cancer. Author manuscript; available in PMC 2010 July 1.
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evident. In addition, we replicated earlier findings showing that all but one (high blood
pressure) of the individual MetS components were positively associated with increased risk of
all-cancer death. A reduction in cancer deaths may result from the prevention or control of
abnormalities associated with MetS. Future investigations should focus on determining the
possible mechanisms associated with the increased risk of cancer mortality, along with the
progression to death through which the abnormalities associated with MetS produce their
effect. Considering the increasing number of pharmacological therapies becoming available
and prescribed for these metabolic abnormalities, it is imperative that the extents to which these
treatments can reduce overall cancer mortality are fully understood.
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Figure 1. Survival free of all-cause cancer across metabolic syndrome status. MetSyn=metabolic
syndrome
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Table 1

Baseline Characteristics According to Metabolic Syndrome Status
Metabolic Syndrome

NIH-PA Author Manuscript

No

Yes

23962

9268

Age, y

44.0 ± 9.6

47.2 ± 9.8

<0.0001

Maximal cardiorespiratory fitness, METs

12.4 ± 2.4

10.1 ± 2.1

<0.0001

n

2

P value

Body mass index, kg/m

25.4 ± 2.9

29.6 ± 4.5

<0.0001

Height, cm

178.8 ± 6.5

179.3 ± 8.2

<0.0001

Waist, cm

90.5 ± 8.6

103.1 ± 12.0

<0.0001

Total cholesterol

5.3 ± 1.0

5.8 ± 1.1

<0.0001

HDL-C

1.3 ± 0.3

1.0 ± 0.2

<0.0001

Triglycerides

1.2 ± 0.7

2.5 ± 2.0

<0.0001

5.4 ± 0.7

6.1 ± 1.4

<0.0001

Systolic

119 ± 13

128 ± 14

<0.0001

Diastolic

79 ± 9

86 ± 10

<0.0001

20.6

35.1

<0.0001

Never smoker

71.4

62.8

Past smoker

12.7

16.8

Current smoker

15.9

20.4

36.9

30.7

<0.0001

Hypercholesterolemia

16.5

30.3

<0.0001

Hypertension

20.9

58.4

<0.0001

Diabetes

2.1

11.0

<0.0001

Cardiovascular disease

1.5

3.4

<0.0001

Family history of cancer, %

23.6

31.0

<0.0001

Abdominal obesity†

7.2

55.9

<0.0001

High blood pressure‡

32.1

76.8

<0.0001

High triglycerides§

13.6

75.7

<0.0001

Low HDL-C¶

19.7

70.3

<0.0001

High glucose ‖

33.6

76.9

<0.0001

Fasting lipids, mmol/L

Fasting blood glucose, mmol/L
Blood pressure, mmHg

NIH-PA Author Manuscript

Physically inactive, %
Smoking status, %

≥ 5 Alcohol drinks per week, %

<0.0001

Chronic medical condition*, %

Metabolic syndrome criteria met, %

NIH-PA Author Manuscript

HDL-C= high-density lipoprotein cholesterol.
Data shown as mean±SD unless specified otherwise
*

Chronic medical condition was defined as the following: hypercholesterolemia (history of physician diagnosed high cholesterol or measured fasting total
cholesterol ≥ 240 mg/dL [6.20 mmol/L]); hypertension (history of physician diagnosis or resting SBP ≥140 mmHg or DBP ≥90 mmHg); diabetes (history
of physician diagnosis, or use of insulin or measured fasting glucose ≥ 126 mg/dL [7.0 mmol/L]); cardiovascular disease (personal history of physician
diagnosed myocardial infarction or stroke).

Eur J Cancer. Author manuscript; available in PMC 2010 July 1.

Jaggers et al.

Page 11

†
Abdominal obesity was defined as waist girth >102 cm [40 in]
‡
High blood pressure was defined as systolic blood pressure≥ 130 mm Hg, diastolic blood pressure ≥85 mm Hg, or history of physician-diagnosed
hypertension

NIH-PA Author Manuscript

§

High triglycerides was defined as triglycerides ≥1.69 mmol/L (150 mg/dL)

¶
Low HDL-C was defined as HDL <1.04 mmol/L (40 mg/dL)
‖

High glucose was defined as glucose≥100 mg/dL or history of physician-diagnosed diabetes
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Metabolic syndrome*
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2353

Yes

HR, hazard ratios; CI, confidence interval.

18055

No

High glucose

21985

378

307

290

395

259

10284

Yes

426

No

Low HDL-C

Yes

No

358

327

22946

14808

High triglycerides

18422

Yes

180

No

High blood pressure

Yes

No

Abdominal obesity

Individual metabolic syndrome
components

265

185

6915

9268

≥3

505

7989

2

86
149

26315

9489

Linear Trend P

6484

265

9268

1

420

Deaths

23962

N

0

No. of Metabolic syndrome risk
factors

Yes

No

NIH-PA Author Manuscript
Table 2

1.26 (1.09-1.47)

1.0 (Referent)

1.36 (1.17-1.59)

1.0 (Referent)

1.37 (1.17-1.60)

1.0 (Referent)

1.16 (0.99-1.35)

1.0 (Referent)

1.51 (1.27-1.79)

1.0 (Referent)

0.003

<0.0001

<0.0001

0.06

1.22 (1.04-1.42)

1.0 (Referent)

1.25 (1.06-1.46)

1.0 (Referent)

1.25 (1.06-1.47)

1.0 (Referent)

1.11 (0.95-1.30)

1.0 (Referent)

1.28 (1.06-1.55)

1.0 (Referent)

<0.0001

<0.0001

1.33 (1.01-1.73)

1.02 (0.78-1.34)

1.0 (Referent)

1.41 (1.19-1.66)

1.0 (Referent)

HR (95% CI)

1.62 (1.24-2.10)

<0.0001

<0.0001

P

1.83 (1.43-2.34)

1.41 (1.09-1.83)

1.05 (0.84-1.37)

1.0 (Referent)

1.56 (1.34-1.82)

1.0 (Referent)

HR (95% CI)

Age-adjusted model

Fully adjusted model †

NIH-PA Author Manuscript

HRs and 95% CIs for All-cause Cancer Mortality Associated with Metabolic Syndrome

0.01

0.007

0.009

0.18

0.01

<0.0001

P
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Defined as the presence of ≥3 of the 5 metabolic risk factors.

NIH-PA Author Manuscript

†
Adjusted for age, examination year, height, smoking status, alcohol intake, physically inactive, hypercholesterolemia, cardiovascular disease, family history of cancer, and cardiorespiratory fitness.
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*
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Outcomes (anatomic site)

13

Yes

Defined as the presence of ≥3 of the 5 metabolic risk factors.

21

27

Yes
No

30

20

No

Yes

27

68

Yes
No

89

Deaths

No

Presence of
Metabolic
syndrome

1.43 (0.71-2.85)

1.0 (Referent)

2.15 (1.27-3.62)

1.0 (Referent)

1.72 (0.97-3.08))

1.0 (Referent)

1.87 (1.36-2.57)

1.0 (Referent)

HR (95% CI)

Age-adjusted model

0.31

0.004

0.066

0.0001

P

1.32 (0.63-2.77)

1.0 (Referent)

1.71 (0.98-3.01)

1.0 (Referent)

1.51 (0.81-2.83)

1.0 (Referent)

1.47 (1.04-2.06)

1.0 (Referent)

HR (95% CI)

Fully adjusted model †

0.47

0.06

0.20

0.03

P

†
Adjusted for age, examination year, height, smoking status, alcohol intake, physically inactive, hypercholesterolemia, cardiovascular disease, family history of cancer, and cardiorespiratory fitness.

*

HR, hazard ratios; CI, confidence interval.

Prostate

Colon and rectum

Colon

Lung

NIH-PA Author Manuscript
Table 3
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HR (95% CI) for Cause-specific Cancer Mortality Associated with Metabolic Syndrome*
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Table 4

HRs and 95% CIs for All-cause Cancer Mortality Associated with Metabolic Syndrome According to Other
Risk Factors

NIH-PA Author Manuscript

Presence of Metabolic Syndrome
No

Yes

N

Deaths

HR (95% CI)

<25

12458

244

1.00

1.44 (1.02-2.02)

≥25

20772

441

1.09 (0.90-1.32)

1.48 (1.20-1.83)

Body mass index (kg/m2)

Age (years)
20-39

11902

78

1.00

1.03 (0.60-1.78)

40-59

18623

425

1.11 (0.78-1.57)

1.68 (1.16-2.43)

≥60

2705

182

1.20 (0.70-2.08)

1.54 (0.89-2.66)

Never smoker

22924

454

1.00

1.43 (1.16-1.74)

Past smoker

4606

52

0.91 (0.59-1.40)

1.35 (0.85-2.13)

Current smoker

5700

179

1.70 (1.35-2.14)

2.29 (1.74-3.00)

Smoking status

NIH-PA Author Manuscript

HR, hazard ratios; CI, confidence interval.
All analyses were adjusted for age, examination year, height, smoking status, alcohol intake, physically inactive, hypercholesterolemia, cardiovascular
disease, family history of cancer, and cardiorespiratory fitness.
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